7MM Duchenne muscular dystrophy market to more than double by 2033

Its expansion is attributed to the treatment of ambulatory DMD patients.

The Duchenne muscular dystrophy (DMD) market across seven major markets (7MM) is projected to grow from $2.3b in 2023 to $5.2b in 2033, according to GlobalData.

The sector’s expansion is attributed to the treatment of ambulatory DMD patients. Moreover, recent approvals of innovative therapies drive market growth.

In line with this, exon-skipping therapies dominate the therapeutic landscape, generating approximately $1b in sales in the 7MM in 2023.

“The DMD treatment landscape is evolving with the emergence of novel therapies such as exon-skipping and gene therapies,’ said Asiyah Nawab, Healthcare Analyst at GlobalData.

“However, gene therapies in particular, compared to exon-skipping, will have less of an impact due to the small patient share eligible for treatment, in addition to the high cost of these medicines limiting patient’s access,” Nawab added.

*7MM = US, France, Germany, Italy, Spain, UK, and Japan